Drug Trial Radar · NCT05060822
Phase ll Study of HEC585 in Patients With IPF
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Jun 30, 2021
Primary completion
Jul 16, 2025
Study completion Dec 11, 2026
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
HEC585Drug
HEC585 Tablets,once daily
PirfenidoneDrug
Pirfenidone,three times a day
PlaceboDrug
Placebo,once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 24 in %FVC compared with placeboTime frame: 24 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.